Deridre Kelly: Ph2 Capmatinib in METex14 NSCLC

Deridre Kelly, Professor of Paediatric Hepatology at the University of Birmingham, sharen on X:

“New The Lancet Oncology – Phase2 Capmatinib in METex14 NSCLC

 Objective response rate: 68%

 Progression-free survival: 12.5 months

 Overall survival: 21.4 months (1st-line), 16.8 months (later lines)

 Adverse Events: edema 47%, nausea 35%, creatinine 21%, vomiting 20%

METex14 key biomarker for METi.”

Source: Deridre Kelly/X